Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.65 |
| ▸ | TP53 | P04637 | 4/20 | 0.63 |
| ▸ | LMNA | P02545 | 2/20 | 0.63 |
| ▸ | MAPT | P10636 | 10/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.63 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4912470 | 0.91 | GAA (0.78) | GAATP53LMNAMAPTALDH1A1 | |
| SCHEMBL4910629 | 0.91 | GAA (0.78) | GAATP53LMNAMAPTALDH1A1 | |
| SCHEMBL4223383 | 0.90 | MAPT (0.63) | GAATP53LMNAMAPTALDH1A1 | |
| SCHEMBL4598292 | 0.89 | MAPT (0.74) | GAATP53LMNAMAPTALDH1A1 | |
| SCHEMBL4910091 | 0.88 | MAPT (0.74) | GAATP53LMNAMAPTALDH1A1 | |
| SCHEMBL4224788 | 0.86 | GAA (0.80) | GAATP53LMNAMAPTALDH1A1 | |
| SCHEMBL4220119 | 0.83 | MAPT (0.69) | GAATP53LMNAMAPTALDH1A1 | |
| SCHEMBL4218366 | 0.82 | TP53 (0.60) | GAATP53LMNAMAPTALDH1A1 | |
| SCHEMBL4223815 | 0.82 | ALDH1A1 (0.67) | GAATP53LMNAMAPTALDH1A1 | |
| SCHEMBL952347 | 0.81 | ALDH1A1 (0.58) | GAATP53LMNAMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090062360-A1 | Compounds Which Inhibit the Glycine Transporter and Uses Thereof | GLAXO GROUP LIMITED (GB) | 2009-03-05 | — | — | US | claimed |
| US-20090062360-A1 | Compounds Which Inhibit the Glycine Transporter and Uses Thereof | GLAXO GROUP LIMITED (GB) | 2009-03-05 | — | — | US | disclosed |
| US-20090062360-A1 | Compounds Which Inhibit the Glycine Transporter and Uses Thereof | GLAXO GROUP LIMITED (GB) | 2009-03-05 | — | — | US | disclosed |
| US-20090062360-A1 | Compounds Which Inhibit the Glycine Transporter and Uses Thereof | GLAXO GROUP LIMITED (GB) | 2009-03-05 | — | — | US | disclosed |
| WO-2007104775-A1 | COMPOUNDS WHICH INHIBIT THE GLYCINE TRANSPORTER AND USES THEREOF | GLAXO GROUP LIMITED (GB) | 2007-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062360-A1 | Compounds Which Inhibit the Glycine Transporter and Uses Thereof | SLC18A2, SLC1A2, SLC1A1 | GAA 202/4885TP53 3543/4885LMNA 4644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.